Metformin is one of the most prescribed diabetes medications in the world. New research suggests it may also be quietly working against the cardiovascular benefits of the exercise you’re counting on to extend your healthy years.
I was diagnosed with Type 2 diabetes at 52. Like a lot of people, I didn’t get there overnight. There were a few years of prediabetic drift first — the slow slide where your numbers are bad enough to worry about but not bad enough to act on aggressively. Eventually I went on metformin. My doctor was right to prescribe it. I don’t second-guess that.
But I’m a competitive bodybuilder. Training isn’t recreational for me — it’s structural. And over time, something started feeling off. The work was there. The gains weren’t keeping pace. I chalked it up to age, because that’s the easy explanation and it’s partially true. After reading this study, I’m not so sure age deserves all the credit.
What the Study Found
A meta-analysis published in The Lancet eClinicalMedicine pooled data from nine randomized controlled trials involving 827 adults with prediabetes or Type 2 diabetes. Participants either followed a structured exercise program while taking metformin, or followed the same protocol without medication.
The cardiovascular results were telling. People on metformin showed measurably less improvement in peak oxygen consumption — VO2 max — the metric most tightly correlated with longevity and long-term cardiovascular health. They also saw less reduction in blood pressure: systolic improved by about 4 mmHg less, diastolic by about 2 mmHg less, compared to the exercise-only group.
Those gaps may sound small in isolation. Compounded over years of serious training, they represent a meaningful difference in cardiovascular age — and in how long, and how well, you live.
What Metformin Is Still Doing Right
This isn’t an argument against metformin. The drug continues to do what it’s designed to do — reducing fasting glucose, glycated hemoglobin, triglyceride levels, and total cholesterol. In the study, there was no significant difference between groups in weight, cholesterol, or standard blood sugar markers.
The interference is happening somewhere more specific: the biological pathways your body uses to adapt to physical training. Researchers point to disruptions in mitochondrial signaling, oxidative stress response, and vascular regulation — the cellular systems that drive cardiovascular adaptation after exercise. Metformin may be dampening those signals without touching the metabolic markers your doctor measures at your annual visit.
Your labs look fine. Your training feels harder than it should. And nobody connects the two.
The Side Effect Nobody Warns You About
While we’re being honest about metformin — let’s talk about the thing most patients discover on their own, usually within the first few weeks: the gas. Relentless, embarrassing, socially inconvenient gas. It’s one of the most common side effects of metformin and one of the least discussed in the exam room.
If you went on metformin and suddenly started wondering whether you’d developed a dairy intolerance, you didn’t. It’s the medication. Metformin affects gut bacteria and the way your digestive system processes certain carbohydrates, which is why the GI disruption — bloating, gas, sometimes diarrhea — is so common, particularly in the early months. The extended-release formulation tends to be easier on the digestive system for many patients, and taking it with food helps. But the conversation should be happening with your doctor at the time of prescription, not discovered by accident at the gym.
When “More Is Better” Doesn’t Apply
Dr. Victoria Finn, endocrinologist at Medical Offices of Manhattan and contributor to LabFinder.com, described the cardiovascular finding as a “dissociation” — the drug’s metabolic function running in one lane while exercise adaptation runs in another.
“These findings don’t completely change our approach to diabetes prevention. But they remind us that metformin and physical exercise are not a universal combination for every patient.” — Dr. Victoria Finn, MD
For anyone managing prediabetes or Type 2 diabetes while trying to protect long-term health, that distinction matters more than it might appear. Life expectancy isn’t just about controlling blood sugar markers — it’s about preserving the physiological capacity that keeps your cardiovascular system functioning well across decades. When a medication designed to protect health is simultaneously limiting the body’s ability to adapt and grow stronger from exercise, that tradeoff deserves a direct conversation with your physician.
Exercise First. Always.
Dr. Finn recommends prioritizing lifestyle modifications before reaching for pharmaceutical support. Her hierarchy: cardiovascular exercise, resistance training, nutritional improvement, sleep optimization, and weight reduction — established and assessed before layering medication on top.
“I wouldn’t overreact to these findings. Metformin remains a beneficial and well-studied option for higher-risk patients as an add-on to an exercise routine. But it should not be viewed as a replacement for lifestyle modification.” — Dr. Victoria Finn, MD
The research on exercise and longevity is unambiguous. Regular cardio and resistance training improve insulin sensitivity, lower blood pressure, strengthen the heart, enhance metabolic flexibility, and — critically — increase VO2 max. That last one matters most. VO2 max is one of the strongest predictors of how long you’ll live. Exercise is how you build it. Protecting that adaptation process is not optional if extending your healthspan is the goal.
What You Can Do About It
The study’s authors recommend that clinicians consider exercise-first protocols where clinically appropriate, and where metformin is prescribed, they suggest examining timing and dosing more carefully to avoid blunting the physical training response. Closer, more individualized monitoring of cardiovascular fitness and blood pressure in patients on both therapies is also recommended.
For patients where metformin isn’t appropriate, or where exercise interference is a genuine concern, Dr. Finn pointed to GLP-1 receptor agonists and SGLT2 inhibitors as alternatives worth discussing with your doctor. GLP-1 receptor agonists are particularly relevant for cardiometabolic risk reduction and weight management — both meaningful longevity levers. SGLT2 inhibitors offer documented cardiovascular and kidney protection. Neither is a direct substitute for metformin, and each carries its own indication and contraindication profile.
The Bottom Line
If you were diagnosed with prediabetes and eventually moved to metformin — as millions of people do — and you’re also exercising seriously, this study is relevant to your life. Not as a reason to stop the medication. As a reason to have a more specific conversation with your doctor about whether your current protocol is actually serving your long-term cardiovascular health, or just your lab numbers.
I’ve been living this. The training doesn’t lie. If your effort isn’t producing the results it should, and metformin is part of your daily routine, it may not be your age. It may not be your program. It may be worth asking the question.
VO2 max is one of the most reliable predictors of lifespan we have. Exercise builds it. Make sure what you’re taking isn’t quietly tearing it down.
Source
“Common Diabetes Drug May Limit Some Exercise Benefits,” George Citroner, The Epoch Times (May 27–28, 2026). Meta-analysis published in The Lancet eClinicalMedicine, nine randomized controlled trials, 827 adult participants. Expert commentary: Victoria Finn, MD, endocrinologist, Medical Offices of Manhattan / LabFinder.com.